ABSI is a clinical data story before it is a revenue story: ABS-201 could validate the AI-biologics platform, but Q1 2026 still shows tiny partner revenue, heavy R&D burn, and no product sales.
References
Sources used in this report
SEC issuer filing indexSEC submissions index for Absci Corporation2026-05-13 · CIK, ticker, exchange, SIC, fiscal year end, filer category, address, and filing inventory.SEC company factsSEC XBRL company facts for Absci Corporation2026-05-13 · Cross-checks for revenue, R&D expense, net loss, cash, securities, assets, liabilities, and operating cash flow.Annual reportAbsci FY2025 Form 10-K2026-03-24 · Business model, platform, pipeline, partnerships, risk factors, liquidity, financing history, IP, and regulation.Quarterly reportAbsci Q1 2026 Form 10-Q2026-05-07 · Latest quarterly financials, cash and securities, accumulated deficit, revenue concentration, liquidity, partner model, and risk updates.Company earnings releaseAbsci Q1 2026 results release2026-05-07 · ABS-201 trial progress, ABS-202 pipeline addition, Q1 revenue, R&D, net loss, cash runway, and 2026 clinical milestones.Investor presentationAbsci May 2026 corporate presentation2026-05-07 · Pipeline stage map, platform positioning, trial design, and company-disclosed facility and team context.Proxy statementAbsci 2026 DEF 14A2026-04-22 · Annual meeting, shares outstanding, board structure, executive officers, governance, and emerging growth company status.Company earnings releaseAbsci FY2025 results release2026-03-24 · FY2025 revenue, R&D expense, net loss, year-end cash and securities, early ABS-201 dosing, and FY2026 outlook.ClinicalTrials.govABS-201 HEADLINE clinical-trial record2026-05-13 · Recruiting status, Phase 1/2 classification, sponsor, conditions, start date, and primary completion date.Peer annual reportRecursion Pharmaceuticals FY2025 Form 10-K2026-02-25 · Official peer-filing context for technology-enabled drug discovery and platform-biotech risk.Peer annual reportSchrodinger FY2025 Form 10-K2026-02-25 · Official peer-filing context for computational drug discovery and software-plus-pipeline commercialization risk.